Quantcast

Latest H5N1 clinical trials Stories

fe9dff98e451ba286dd7a495937cd063
2010-12-07 07:53:07

Only the fragile chicken egg stands between Americans and a flu pandemic that would claim tens of thousands more lives than are usually lost to the flu each year. Vaccine production hinges on the availability of hundreds of millions of eggs "“ and even with the vaccine, flu still claims somewhere around 36,000 lives in the United States during a typical year. Now scientists have taken an important step toward ending the dominance of the oval. In a paper published in the Dec. 6 issue of...

2010-11-29 08:00:00

SWIFTWATER, Pennsylvania, November 29, 2010 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a...

2010-11-11 03:52:00

ITTIGEN and BERN, Switzerland, November 11, 2010 /PRNewswire/ -- Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide. Vaccination of the first study group has been completed and demonstrated that PEV7 is safe and well-tolerated in all subjects and...

2010-11-04 01:00:00

LYON, France, November 4, 2010 /PRNewswire-FirstCall/ -- - First Phase 3 Study Underway in Australia Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most clinically advanced dengue vaccine candidate(1,2), entered its first phase 3 clinical study in Australia. This study is part of a global phase 3...

2010-11-02 06:00:00

PRINCETON, N.J., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, reported today that it has completed enrollment of its Phase 1B clinical trial of RiVax(TM), a ricin subunit vaccine, in healthy volunteers. Preliminary results indicate that RiVax(TM) appears safe at all doses tested in volunteers. This trial is designed to assess the duration of immune responses using an adjuvant formulation...

2010-11-01 06:00:00

QUEBEC CITY , Nov. 1 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway. The Phase II randomized, placebo controlled clinical...

2010-10-25 07:45:00

SWIFTWATER, Pa., Oct. 25 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the results of a clinical trial of its investigational Fluzone® Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine). Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual...

2010-10-25 07:45:00

SWIFTWATER, Pa., Oct. 25 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the results of the Phase III clinical trial of its investigational Fluzone® Intradermal (Influenza Virus Vaccine) candidate compared to Fluzone (Influenza Virus Vaccine) administered via the traditional intramuscular method (IM). Data from the clinical trial assessing the immunogenicity and safety of the investigational...

2010-10-18 06:30:00

ATLANTA, Oct. 18 /PRNewswire/ -- Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN). In the article, titled "Search for Effective HIV Vaccine Intensifies: Progress to Date Result of Robust Funding and Cooperation...

2010-10-08 14:00:00

SWIFTWATER, Pa., Oct. 8 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has been awarded a three-year contract for $56.94 million by the U.S. Department of Health and Human Services (HHS) to maintain flocks to enable manufacturing pandemic influenza vaccine at full capacity on a year-round basis. The contract supported by the HHS Biomedical Advanced Research and Development Authority (BARDA) affords rapid response and...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.